GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Allopurinol - ALOPRIM intravenous infusion

Local official-label summaryBase record retrieved 2026-09-09See the evidence for this drug2 sources available - open source summaries, references and comparisons

ALOPRIM / allopurinol IV / allopurinol injection

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (2)
Review first - source-specific qualification

Before use: Allopurinol - ALOPRIM intravenous infusion

IV cancer-supportive dosing remains separate from oral gout initiation. This is a generic IV label, not a freshly reconciled ALoprim branded preparation monograph.

Before applying: Keep indication, IV product and total daily units attached; confirm exact vial preparation separately.

Evidence for this qualification

Source-specific interpretation; independent clinician adjudication pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
The adult cancer-therapy renal table is not a gout or pediatric table

ALOPRIM provides a distinct IV adult renal/dialysis table. Severe-renal and dialysis pediatric treatment was not studied.

Before applying: Keep route, cancer-therapy indication and age scope visible. Check the complete infusion instructions.

Also check: The adult cancer-therapy renal table is not a gout or pediatric table

Official source

Allopurinol for injection - exact generic IV label

Product / population
Adults with cancer-therapy hyperuricemia who cannot tolerate oral therapy; IV formulation.
Renal measure
Creatinine clearance, mL/min.

Renal guidance and important limits

Limits that apply to these rows

These are total daily amounts, not doses per infusion. The selected table does not establish pediatric severe-renal or dialysis dosing.

Review uric acid, renal function and interacting azathioprine/mercaptopurine therapy. This generic product label does not newly verify every ALoprim preparation detail.

Allopurinol IV - adult renal total daily dose
CrCl (mL/min)Source-specific instruction
10-20200 mg/day
<10100 mg/day
Dialysis guidance - separate source-specific schedules
Allopurinol IV - adult dialysis
SettingSource-specific instruction
On dialysis50 mg every 12 hours OR 100 mg every 24 hours
Read the retained text before reformatting

Allopurinol IV - adult renal total daily dose

CrCl (mL/min)Source-specific instruction
10-20200 mg/day
<10100 mg/day

Allopurinol IV - adult dialysis

SettingSource-specific instruction
On dialysis50 mg every 12 hours OR 100 mg every 24 hours

These are total daily amounts, not doses per infusion. The selected table does not establish pediatric severe-renal or dialysis dosing.

Review uric acid, renal function and interacting azathioprine/mercaptopurine therapy. This generic product label does not newly verify every ALoprim preparation detail.

Source revision: 10/2022 | Retrieved: 2026-09-10. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2caf5eed-2408-4ce0-bd0d-04f4c90e434d

Scope: Selected source sections stored locally. Not a complete monograph or independent clinical approval. GlobalRPh v6.6.

Full source card / provenance

Other formulations / related references (1)

Confirm the exact product. These links do not imply interchangeable doses or indications.

AllopurinolRelated reference only; not an interchangeable dose or indication.
All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 2 source difference / applicability notes

Official product label

Allopurinol for injection - exact generic IV label

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Keep indication, IV product and total daily units attached; confirm exact vial preparation separately.

Adults with cancer-therapy hyperuricemia who cannot tolerate oral therapy; IV formulation.

Renal method: Creatinine clearance, mL/min.
Retrieved: 2026-09-10

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - ALOPRIM

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

ALOPRIM IV for cancer-therapy-associated uric-acid elevations when oral treatment cannot be tolerated. The numerical renal table is for adults.

Renal method: CrCl, mL/min; adult renal table with a separate dialysis row
Retrieved: 2026-09-09

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

The adult cancer-therapy renal table is not a gout or pediatric tableBefore use: Allopurinol - ALOPRIM intravenous infusion

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 2 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

route indication and age

The adult cancer-therapy renal table is not a gout or pediatric table

ALOPRIM provides a distinct IV adult renal/dialysis table. Severe-renal and dialysis pediatric treatment was not studied.

How to use this: Keep route, cancer-therapy indication and age scope visible. Check the complete infusion instructions.

GlobalRPh RX List - ALOPRIMAllopurinol

Source-specific interpretation; independent clinician adjudication pending.

source scope and renal guidance

Before use: Allopurinol - ALOPRIM intravenous infusion

IV cancer-supportive dosing remains separate from oral gout initiation. This is a generic IV label, not a freshly reconciled ALoprim branded preparation monograph.

How to use this: Keep indication, IV product and total daily units attached; confirm exact vial preparation separately.

Allopurinol for injection - exact generic IV label

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeAllopurinol for injection - exact generic IV labelGlobalRPh RX List - ALOPRIM
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/aloprim-drug/

Exact product and population

ALOPRIM IV for cancer-therapy-associated uric-acid elevations when oral treatment cannot be tolerated. The numerical renal table is for adults.

RDM55-SCOPE-allopurinol-aloprim-iv · Source section: Selected source product scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Allopurinol for injection - exact generic IV label

Open original reference

Open / share this exact local source

DailyMed / NLM exact product labeling · Adults with cancer-therapy hyperuricemia who cannot tolerate oral therapy; IV formulation.

Renal method: Creatinine clearance, mL/min.
Source date: 10/2022
Retrieved: 2026-09-10

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Keep indication, IV product and total daily units attached; confirm exact vial preparation separately.

Selected source sections stored locally. Not a complete monograph or independent clinical approval.

Renal guidance and important limits

Limits that apply to these rows

These are total daily amounts, not doses per infusion. The selected table does not establish pediatric severe-renal or dialysis dosing.

Review uric acid, renal function and interacting azathioprine/mercaptopurine therapy. This generic product label does not newly verify every ALoprim preparation detail.

Allopurinol IV - adult renal total daily dose
CrCl (mL/min)Source-specific instruction
10-20200 mg/day
<10100 mg/day
Dialysis guidance - separate source-specific schedules
Allopurinol IV - adult dialysis
SettingSource-specific instruction
On dialysis50 mg every 12 hours OR 100 mg every 24 hours
Read the retained text before reformatting

Allopurinol IV - adult renal total daily dose

CrCl (mL/min)Source-specific instruction
10-20200 mg/day
<10100 mg/day

Allopurinol IV - adult dialysis

SettingSource-specific instruction
On dialysis50 mg every 12 hours OR 100 mg every 24 hours

These are total daily amounts, not doses per infusion. The selected table does not establish pediatric severe-renal or dialysis dosing.

Review uric acid, renal function and interacting azathioprine/mercaptopurine therapy. This generic product label does not newly verify every ALoprim preparation detail.

RDM64-official-allopurinol-aloprim-iv-8e5d3004ae-C1 · Source locator: Sections 1, 2.2 Table 2, 5.2, 7 and 8.6.

Source-specific limits

These are total daily amounts, not doses per infusion. The selected table does not establish pediatric severe-renal or dialysis dosing.

Review uric acid, renal function and interacting azathioprine/mercaptopurine therapy. This generic product label does not newly verify every ALoprim preparation detail.

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2caf5eed-2408-4ce0-bd0d-04f4c90e434d
Retrieved
2026-09-10
Exact label title
Allopurinol for injection - exact generic IV label
DailyMed Set ID
2caf5eed-2408-4ce0-bd0d-04f4c90e434d
Label revision
10/2022
Renal-function method
Creatinine clearance, mL/min.
Source date/version
10/2022
Hash meaning
Local authored summary, not source HTML/XML/PDF bytes
Local summary SHA-256
6c7c7a1f46fe89c1d182730e3479f8ee6c49fbfd2fa00985207557946c4ffcf5
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - ALOPRIM

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · ALOPRIM IV for cancer-therapy-associated uric-acid elevations when oral treatment cannot be tolerated. The numerical renal table is for adults.

Renal method: CrCl, mL/min; adult renal table with a separate dialysis row
Source date: 2/2022
Retrieved: 2026-09-09

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The adult renal table specifies 200 mg/day at CrCl 10-20 mL/min, 100 mg/day below 10, and on dialysis either 50 mg every 12 hours or 100 mg every 24 hours. These are IV cancer-therapy instructions, not a gout regimen. Monitor serum uric acid at least daily and individualize dose and frequency to keep it within the normal range.

Severe-renal and dialysis treatment has not been studied in pediatric patients; assess risks and benefits rather than transferring the adult table. Reconstitution, further dilution, infusion compatibility and the full treatment course must be checked in the original prescribing information.

RDM55-rxlist-allopurinol-aloprim-iv-4c98e3dcf5-C1 · Source locator: Indications; Recommended Dosage; Table 2 adult renal dosing; pediatric severe-renal limitation

Source-specific limits

Selected sections only. A hosted mirror is not independent confirmation of the underlying label.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/aloprim-drug/
Retrieved
2026-09-09
Renal-function method
CrCl, mL/min; adult renal table with a separate dialysis row
Source date/version
2/2022
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
e2741530723751d16f5e7f1cd874d15e1c458056e0d048b6b828aaa5680a19fe

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/aloprim-drug/
Source retrieval
2026-09-09. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
d89a7ed72f8dc5b3388dc4acfe84b255b51f3530373b8efcf0c94c0ad84d24e1
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report